GlassScriptPhysician profile
Thomas J Pfiffner
NPI 1477780054
$10,648.00
in general payments reported to CMS, 2019-2025
69 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $1,230 · 2021: $2,157 · 2022: $1,853 · 2023: $2,542 · 2024: $1,371 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $1,374.05 | 2019-2025 | Gocovri, Apokyn, Gocovri |
| Teva Pharmaceuticals USA, INC. | $816.69 | 2019-2024 | Austedo Xr, Ajovy, Austedo |
| Sk Life Science, INC. | $564.95 | 2020-2023 | |
| Lundbeck LLC | $525.47 | 2020-2024 | Vyepti, Rexulti |
| Jazz Pharmaceuticals INC. | $504.27 | 2021-2023 | |
| Amgen INC. | $432.99 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $403.63 | 2020-2023 | Relistor |
| Ucb, INC. | $390.20 | 2020-2024 | Nayzilam, Rystiggo, Fintepla |
| Abbvie INC. | $319.39 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $267.12 | 2020-2021 | |
| Allergan, INC. | $249.99 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $233.33 | 2019-2024 | Rytary, Lyvispah |
| Livanova USA, INC. | $218.78 | 2021-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $213.36 | 2019-2023 | Soliris |
| Abbott Laboratories | $208.52 | 2019-2023 | Octrode |
Show all 68 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$762,778.42 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pfiffner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.